Compare RGS & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGS | GNTA |
|---|---|---|
| Founded | 1922 | 2014 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.7M | 62.7M |
| IPO Year | 1994 | 2021 |
| Metric | RGS | GNTA |
|---|---|---|
| Price | $27.00 | $1.07 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.1K | ★ 38.2K |
| Earning Date | 05-06-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.24 | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $210,134,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $30.34 | ★ N/A |
| Revenue Growth | ★ 3.52 | N/A |
| 52 Week Low | $19.31 | $0.55 |
| 52 Week High | $31.50 | $10.00 |
| Indicator | RGS | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 46.12 | 34.07 |
| Support Level | $25.96 | $0.58 |
| Resistance Level | $28.44 | $1.70 |
| Average True Range (ATR) | 0.96 | 0.08 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 16.22 | 16.06 |
Regis Corporation owns, franchises, and operates beauty salons in North America and the U.K., serving mainly price-conscious customers. Its salons, located mostly in strip malls, shopping centers, and Walmart stores, offer services like haircutting, styling, shampooing, conditioning, and hair coloring, along with hair care and beauty products. The company's primary brands include Supercuts, SmartStyle, and Cost Cutters. Regis generates the majority of its revenue from these mass-market locations and reports operations in two segments: franchise and company-owned, with services making up about 94% of company-owned salon sales.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon, a product to treat glioblastoma multiforme, a solid tumor affecting the brain.